Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. Social Networks
  11. External Links
  12. Analytics And Tracking
  13. Libraries
  14. Hosting Providers
  15. CDN Services

We began analyzing https://www.nature.com/articles/nrd.2018.71, but it redirected us to https://www.nature.com/articles/nrd.2018.71. The analysis below is for the second page.

Title[redir]:
RNA-modifying proteins as anticancer drug targets | Nature Reviews Drug Discovery
Description:
Covalent modifications of RNA β€” mediated by RNA-modifying proteins (RMPs) β€” affect RNA stability and translation to proteins, and some of these RMPs have been implicated in cancer. Here, Copeland and colleagues review the current understanding of RNA modifications with a focus on mRNA methylation and assess the potential of RMPs as novel anticancer targets. All major biological macromolecules (DNA, RNA, proteins and lipids) undergo enzyme-catalysed covalent modifications that impact their structure, function and stability. A variety of covalent modifications of RNA have been identified and demonstrated to affect RNA stability and translation to proteins; these mechanisms of translational control have been termed epitranscriptomics. Emerging data suggest that some epitranscriptomic mechanisms are altered in human cancers as well as other human diseases. In this Review, we examine the current understanding of RNA modifications with a focus on mRNA methylation, highlight their possible roles in specific cancer indications and discuss the emerging potential of RNA-modifying proteins as therapeutic targets.

Matching Content Categories {πŸ“š}

  • Education
  • Science
  • Business & Finance

Content Management System {πŸ“}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {πŸ“ˆ}

What is the average monthly size of doi.org audience?

πŸ™οΈ Massive Traffic: 50M - 100M visitors per month


Based on our best estimate, this website will receive around 96,105,781 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {πŸ’Έ}

We don’t know how the website earns money.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Doi.org could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {πŸ”}

pubmed, article, google, scholar, cas, central, rna, cell, cancer, biol, chem, nature, human, methylation, protein, nat, res, proteins, methyltransferase, structure, mrna, enzymes, mol, family, nucleic, fto, trna, acids, dna, modifications, domain, structural, nmethyladenosine, basis, drug, discovery, modification, mettl, alkb, med, breast, cells, complex, access, methyltransferases, inhibitors, gene, reveals, binding, recognition,

Topics {βœ’οΈ}

permissions reprints nature portfolio journals privacy policy fe2+β€”Ξ±-kg-dependent dioxygenase superfamily targeting fto/m6a/myc/cebpa signaling nature portfolio body mass index sah s-adenosyl-l-homocysteine adar rna editing advertising posttranscriptional m6a editing cross-linked protein-dna system cell-type-specific methylation patterns nol1/nop2/sun domain family social media hypoxia-inducible microrna-210 regulates mediates myc-induced proliferation alkbh2 mutants cross-linked s-adenosyl-l-methionine high-resolution mapping reveals pi3k/akt signaling pathway guide rna-protein interactions mettl3-mediated m6a modification n6-methyladenosine rna demethylase single-nucleotide-resolution mapping china chem eif4e mrna-cap interaction il-7/stat5/socs pathways protein-protein interaction inhibitors n6-methyladenosine demethylase fto a-dependent translation control editing dna-repair protein alkb n6-methyladenosine-dependent regulation sam-dependent methyltransferase catalysis alkali-stable dinucleotide sequences dimt1-irf4 oncogenic axis oxygen-sensing prolyl hydroxylases /alpha-ketoglutarate-dependent dioxygenases alpha-ketoglutarate-dependent dioxygenases n6-methylated adenosine modification article boriack-sjodin acute mega-karyoblastic leukemia reverse dna/rna damage eif4e cap-binding protein alkbhs-facilitated rna modifications genome-wide meta-analyses m7g-cap-binding mode n6-methyladenosine reader proteins x-ray crystal structural

Questions {❓}

  • Eukaryotic stand-alone pseudouridine synthases β€” RNA modifying enzymes and emerging regulators of gene expression?

Schema {πŸ—ΊοΈ}

WebPage:
      mainEntity:
         headline:RNA-modifying proteins as anticancer drug targets
         description:Covalent modifications of RNA Ҁ” mediated by RNA-modifying proteins (RMPs) Ҁ” affect RNA stability and translation to proteins, and some of these RMPs have been implicated in cancer. Here, Copeland and colleagues review the current understanding of RNA modifications with a focus on mRNA methylation and assess the potential of RMPs as novel anticancer targets. All major biological macromolecules (DNA, RNA, proteins and lipids) undergo enzyme-catalysed covalent modifications that impact their structure, function and stability. A variety of covalent modifications of RNA have been identified and demonstrated to affect RNA stability and translation to proteins; these mechanisms of translational control have been termed epitranscriptomics. Emerging data suggest that some epitranscriptomic mechanisms are altered in human cancers as well as other human diseases. In this Review, we examine the current understanding of RNA modifications with a focus on mRNA methylation, highlight their possible roles in specific cancer indications and discuss the emerging potential of RNA-modifying proteins as therapeutic targets.
         datePublished:2018-05-18T00:00:00Z
         dateModified:2018-05-18T00:00:00Z
         pageStart:435
         pageEnd:453
         sameAs:https://doi.org/10.1038/nrd.2018.71
         keywords:
            Cancer
            Drug discovery
            RNA modification
            Transcriptomics
            Biomedicine
            general
            Pharmacology/Toxicology
            Biotechnology
            Medicinal Chemistry
            Molecular Medicine
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrd.2018.71/MediaObjects/41573_2018_Article_BFnrd201871_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrd.2018.71/MediaObjects/41573_2018_Article_BFnrd201871_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrd.2018.71/MediaObjects/41573_2018_Article_BFnrd201871_Fig3_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrd.2018.71/MediaObjects/41573_2018_Article_BFnrd201871_Fig4_HTML.jpg
         isPartOf:
            name:Nature Reviews Drug Discovery
            issn:
               1474-1784
               1474-1776
            volumeNumber:17
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:P. Ann Boriack-Sjodin
               affiliation:
                     name:Accent Therapeutics, Inc.
                     address:
                        name:Accent Therapeutics, Inc., Cambridge, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Scott Ribich
               affiliation:
                     name:Accent Therapeutics, Inc.
                     address:
                        name:Accent Therapeutics, Inc., Cambridge, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Robert A. Copeland
               affiliation:
                     name:Accent Therapeutics, Inc.
                     address:
                        name:Accent Therapeutics, Inc., Cambridge, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:RNA-modifying proteins as anticancer drug targets
      description:Covalent modifications of RNA Ҁ” mediated by RNA-modifying proteins (RMPs) Ҁ” affect RNA stability and translation to proteins, and some of these RMPs have been implicated in cancer. Here, Copeland and colleagues review the current understanding of RNA modifications with a focus on mRNA methylation and assess the potential of RMPs as novel anticancer targets. All major biological macromolecules (DNA, RNA, proteins and lipids) undergo enzyme-catalysed covalent modifications that impact their structure, function and stability. A variety of covalent modifications of RNA have been identified and demonstrated to affect RNA stability and translation to proteins; these mechanisms of translational control have been termed epitranscriptomics. Emerging data suggest that some epitranscriptomic mechanisms are altered in human cancers as well as other human diseases. In this Review, we examine the current understanding of RNA modifications with a focus on mRNA methylation, highlight their possible roles in specific cancer indications and discuss the emerging potential of RNA-modifying proteins as therapeutic targets.
      datePublished:2018-05-18T00:00:00Z
      dateModified:2018-05-18T00:00:00Z
      pageStart:435
      pageEnd:453
      sameAs:https://doi.org/10.1038/nrd.2018.71
      keywords:
         Cancer
         Drug discovery
         RNA modification
         Transcriptomics
         Biomedicine
         general
         Pharmacology/Toxicology
         Biotechnology
         Medicinal Chemistry
         Molecular Medicine
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrd.2018.71/MediaObjects/41573_2018_Article_BFnrd201871_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrd.2018.71/MediaObjects/41573_2018_Article_BFnrd201871_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrd.2018.71/MediaObjects/41573_2018_Article_BFnrd201871_Fig3_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrd.2018.71/MediaObjects/41573_2018_Article_BFnrd201871_Fig4_HTML.jpg
      isPartOf:
         name:Nature Reviews Drug Discovery
         issn:
            1474-1784
            1474-1776
         volumeNumber:17
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:P. Ann Boriack-Sjodin
            affiliation:
                  name:Accent Therapeutics, Inc.
                  address:
                     name:Accent Therapeutics, Inc., Cambridge, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Scott Ribich
            affiliation:
                  name:Accent Therapeutics, Inc.
                  address:
                     name:Accent Therapeutics, Inc., Cambridge, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Robert A. Copeland
            affiliation:
                  name:Accent Therapeutics, Inc.
                  address:
                     name:Accent Therapeutics, Inc., Cambridge, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Nature Reviews Drug Discovery
      issn:
         1474-1784
         1474-1776
      volumeNumber:17
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Accent Therapeutics, Inc.
      address:
         name:Accent Therapeutics, Inc., Cambridge, USA
         type:PostalAddress
      name:Accent Therapeutics, Inc.
      address:
         name:Accent Therapeutics, Inc., Cambridge, USA
         type:PostalAddress
      name:Accent Therapeutics, Inc.
      address:
         name:Accent Therapeutics, Inc., Cambridge, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:P. Ann Boriack-Sjodin
      affiliation:
            name:Accent Therapeutics, Inc.
            address:
               name:Accent Therapeutics, Inc., Cambridge, USA
               type:PostalAddress
            type:Organization
      name:Scott Ribich
      affiliation:
            name:Accent Therapeutics, Inc.
            address:
               name:Accent Therapeutics, Inc., Cambridge, USA
               type:PostalAddress
            type:Organization
      name:Robert A. Copeland
      affiliation:
            name:Accent Therapeutics, Inc.
            address:
               name:Accent Therapeutics, Inc., Cambridge, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Accent Therapeutics, Inc., Cambridge, USA
      name:Accent Therapeutics, Inc., Cambridge, USA
      name:Accent Therapeutics, Inc., Cambridge, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

Social Networks {πŸ‘}(2)

External Links {πŸ”—}(881)

Analytics and Tracking {πŸ“Š}

  • Google Tag Manager

Libraries {πŸ“š}

  • Prism.js
  • Zoom.js

Emails and Hosting {βœ‰οΈ}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {πŸ“¦}

  • Crossref

7.12s.